The notch pathway is recurrently mutated in diffuse large B-Cell lymphoma associated with hepatitis c virus infection

Haematologica

Volumn 100, Issue 2, 2015, Pages 246-252

  Arcaini, Luca ^a,b   Rossi, Davide ^c   Lucioni, Marco ^b   Nicola, Marta ^a   Bruscaggin, Alessio ^c   Fiaccadori, Valeria ^a   Riboni, Roberta ^b   Ramponi, Antonio ^c   Ferretti, Virginia V ^b   Cresta, Stefania ^c   Casaluci, Gloria Margiotta ^c   Bonfichi, Maurizio ^b   Gotti, Manuel ^b   Merli, Michele ^d   Maffi, Aldo ^a   Arra, Mariarosa ^a   Varettoni, Marzia ^b   Rattotti, Sara ^b   Morello, Lucia ^a   Guerrera, Maria Luisa ^a   Sciarra, Roberta ^a   Gaidano, Gianluca ^c   Cazzola, Mario ^a,b   Paulli, Marco ^a,b   more..

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HOMEODOMAIN PROTEIN; KI 67 ANTIGEN; NOTCH RECEPTOR; NOTCH1 PROTEIN, HUMAN; NOTCH1 RECEPTOR; NOTCH2 PROTEIN, HUMAN; NOTCH2 RECEPTOR; NUCLEAR PROTEIN; SPEN PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER GRADING; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE MUTATION; GENETICS; HEPACIVIRUS; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; ISOLATION AND PURIFICATION; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; MORTALITY; MUTATION; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PATHOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; GENETICS; HEPACIVIRUS; HEPATITIS C; HOMEODOMAIN PROTEINS; HUMANS; ISOLATION AND PURIFICATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MORTALITY; MUTATION; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTOR, NOTCH1; RECEPTOR, NOTCH2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VIROLOGY;

EID: 84964285656     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.116855     Document Type: Article

References (38)

1. de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008;6(4):451-458.
2. Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lym-phomas: an Italian multicenter case-control study. Blood. 2003;102(3):996-999.
3. Saadoun D, Suarez F, Lefrere F, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood. 2005; 105(1):74-76.
4. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with vil-lous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347(2):89-94.
5. Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012; 209(9):1537-1551.
6. Kiel MJ, Velusamy T, Betz BL, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med. 2012;209(9):1553-1565.
7. Bruscaggin A, Monti S, Arcaini L, et al. Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features. Br J Haematol. 2014;167(5):718-720.
8. Xochelli A, Kalpadakis C, Gardiner A, et al. Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity? Blood. 2014;123(8):1199-1206.
9. Besson C, Canioni D, Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol. 2006;24(6):953-960.
10. Visco C, Arcaini L, Brusamolino E, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol. 2006; 17(9):1434-1440.
11. Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-contain-ing chemotherapy regimens: a Japanese multicenter analysis. Blood. 2010;116(24):5119-5125.
12. Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2008.
13. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115-119.
14. Rossi D, Deaglio S, Dominguez-Sola D, et al. Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. Blood. 2011; 118(18):4930-4934.
15. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121(8): 1403-1412.
16. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870): 1676-1679.
17. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88-92.
18. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717-721.
19. Peveling-Oberhag J, Crisman G, Schmidt A, et al. Dysregulation of global microRNA expression in splenic marginal zone lym-phoma and influence of chronic hepatitis C virus infection. Leukemia. 2012;26(7):1654-1662.
20. Zibellini S, Capello D, Forconi F, et al. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica. 2010; 95(10):1792-1796.
21. Paulli M, Arcaini L, Lucioni M, et al. Subcutaneous 'lipoma-like' B-cell lym-phoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. Ann Oncol. 2010;21(6):1189-1195.
22. Mollejo M, Menarguez J, Guisado-Vasco P, et al. Hepatitis C virus-related lymphoprolif-erative disorders encompass a broader clinical and morphological spectrum than previ-ously recognized: a clinicopathological study. Mod Pathol. 2014;27(2):281-293.
23. Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol. 2013; 59(1):169-177.
24. Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-contain-ing chemotherapy regimens: a Japanese multicenter analysis. Blood. 2010; 116(24):5119-5125.
25. Martinez N, Almaraz C, Vaque J P, et al. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. Leukemia. 2014;28(6):1334-1340.
26. Parry M, Rose-Zerilli MJ, Gibson J, et al. Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PloS one. 2013 8(12):e83244.
27. Lee SY, Kumano K, Nakazaki K, et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer science. 2009; 100(5):920-926.
28. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA. 2012; 109(10):3879-3884.
29. Rossi D, Gaidano G. Richter syndrome. Adv Exp Med Biol. 2013;792:173-191.
30. Lossos IS, Gascoyne RD. Transformation of follicular lymphoma. Best Pract Res Clin Haematol. 2011;24(2):147-163.
31. Meyer AH, Stroux A, Lerch K, et al. Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma. Ann Oncol. 2014;25(1):210-215.
32. Ghesquieres H, Berger F, Felman P, et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol. 2006;24(33):5234-5241.
33. Lobry C, Oh P, Mansour MR, Look AT, Aifantis I. Notch signaling: switching an oncogene to a tumor suppressor. Blood. 2014;123(16):2451-2459.
34. Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107(8):3034-3044.
35. Merli M, Visco C, Spina M, et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica. 2014;99(3):489-496.
36. Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lym-phoma and mantle cell lymphoma. J Clin Oncol. 2011;29(6):690-697.
37. Chiappella A, Tucci A, Castellino A, et al. Lenalidomide plus cyclophosphamide, dox-orubicin, vincristine, prednisone and ritux-imab is safe and effective in untreated, elderly patients with diffuse large B-cell lym-phoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica. 2013;98(11):1732-1738.
38. Lopez-Guerra M, Xargay-Torrent S, Rosich L, et al. The gamma-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Leukemia. 2015;29(1):96-106.